Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)

Inclusion Criteria: * Patients treated with the same regimen including 3 HAART from at least 4 months * Aged 18 years or older * Who gave informed consent to the participation to the study * With at least two viral load \< 50 copies/mL in two consecutive determinations at least 6 months apart (tolerance of two weeks) * With CD4 cell count \> 200 cells/μL and absence of any opportunistic infection or AIDS-related disease for at least one year prior to the screening. * With R5 tropism by viral DNA genotyping (geno2pheno "clonal") * With CD4 cell count nadir\>50 cell/mmc or 100 cell/mmc if previous enfuvirtide or integrase inhibitors use Exclusion Criteria: * With at least one major or two minor mutation conferring resistance to darunavir reported in the update list of International AIDS Society - USA , in previous resistance test * Previous D/M or X4 viral tropism * Previous major clinical toxicities (grade \>=3) to the proposed drugs of the study * Pregnancy or breast feeding, desire of pregnancy in the short term * Past exposure to Chemokine Receptor 5 antagonist * HBsAg serostatus * Liver cirrhosis of class C (Child-Pugh) * Sulpha drug hypersensitivity * The presence of major non AIDS-defining diseases that, in the opinion of the investigator, may compromise the retention of the patient in the study for the necessary follow-up period. * Estimated glomerular filtration \< 30 ml/min (cockroft-Gaut; MDRD formula if black-African or african-american) at screening visit * Hypertransaminasemia of grade IV (more than 10 times the upper normal limit) at screening visit